← Back to Search

Technology-Enhanced Communication for Multiple Sclerosis

N/A
Waitlist Available
Led By Ellen Mowry
Research Sponsored by Johns Hopkins University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Starting one of the following MS therapies: injectable (subcutaneous interferon beta or glatiramer acetate) or oral (fingolimod, teriflunomide, or dimethyl fumarate) therapies
Expanded Disability Status Scale (EDSS) score of 6.0 or less
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 96 weeks
Awards & highlights
No Placebo-Only Group

Summary

This trial will help create a questionnaire to confirm relapses in MS patients and study if communication with providers improves patient care.

Who is the study for?
This trial is for English-speaking individuals with relapsing-remitting MS who have had at least two relapses in the past two years or one recent onset of RRMS. Participants must own a smartphone or be willing to use one, live within 100 miles of Johns Hopkins Medical Center, and have an EDSS score of 6.0 or less.
What is being tested?
The study aims to develop a questionnaire that can confirm MS relapses without needing an office visit. It will also assess if better communication with healthcare providers via technology improves patient care and satisfaction.
What are the potential side effects?
Since this trial focuses on communication improvements rather than medication, there are no direct side effects from interventions being tested. However, participants may experience general discomfort related to their condition.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am starting a new MS therapy, either an injection or a pill.
Select...
My disability level allows me to walk at least 100 meters without aid or rest.
Select...
I have been diagnosed with relapsing-remitting MS.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~96 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 96 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Blinded

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: ExperimentalExperimental Treatment1 Intervention
A different kind of communication with the clinic will be used.
Group II: ControlActive Control1 Intervention
One kind of communication with the clinic will be used.

Find a Location

Who is running the clinical trial?

BiogenIndustry Sponsor
646 Previous Clinical Trials
467,363 Total Patients Enrolled
227 Trials studying Multiple Sclerosis
142,008 Patients Enrolled for Multiple Sclerosis
Johns Hopkins UniversityLead Sponsor
2,326 Previous Clinical Trials
14,874,579 Total Patients Enrolled
30 Trials studying Multiple Sclerosis
2,418 Patients Enrolled for Multiple Sclerosis
Ellen MowryPrincipal InvestigatorJohns Hopkins University

Media Library

Communication with the clinic Clinical Trial Eligibility Overview. Trial Name: NCT02454907 — N/A
Multiple Sclerosis Research Study Groups: Experimental, Control
Multiple Sclerosis Clinical Trial 2023: Communication with the clinic Highlights & Side Effects. Trial Name: NCT02454907 — N/A
Communication with the clinic 2023 Treatment Timeline for Medical Study. Trial Name: NCT02454907 — N/A
~19 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top